NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Forecast & News

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.02. View Achillion Pharmaceuticals' Earnings History.

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Achillion Pharmaceuticals.

5 analysts have issued twelve-month price objectives for Achillion Pharmaceuticals' stock. Their forecasts range from $2.50 to $6.30. On average, they expect Achillion Pharmaceuticals' share price to reach $5.03 in the next year. This suggests that the stock has a possible downside of 19.3%. View Analyst Price Targets for Achillion Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.

News coverage about ACHN stock has trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Achillion Pharmaceuticals.

Achillion Pharmaceuticals saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 8,950,000 shares, an increase of 11.5% from the September 15th total of 8,030,000 shares. Based on an average trading volume of 2,990,000 shares, the short-interest ratio is currently 3.0 days. Approximately 6.6% of the shares of the company are sold short. View Achillion Pharmaceuticals' Current Options Chain.

Some companies that are related to Achillion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Gilead Sciences (GILD), Eiger Biopharmaceuticals (EIGR), Iconix Brand Group (ICON), ACADIA Pharmaceuticals (ACAD), Edap Tms (EDAP) and Celldex Therapeutics (CLDX).

Achillion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (3.21%), Millennium Management LLC (2.35%), Alps Advisors Inc. (0.20%), Squarepoint Ops LLC (0.19%), Rhumbline Advisers (0.16%) and California Public Employees Retirement System (0.15%). Company insiders that own Achillion Pharmaceuticals stock include David Scheer and Joseph Truitt. View Institutional Ownership Trends for Achillion Pharmaceuticals.

ACHN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Man Group plc, SG Americas Securities LLC and Alps Advisors Inc.. Company insiders that have sold Achillion Pharmaceuticals company stock in the last year include David Scheer and Joseph Truitt. View Insider Buying and Selling for Achillion Pharmaceuticals.

ACHN stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, California Public Employees Retirement System, Bourgeon Capital Management LLC, Rhumbline Advisers, Meeder Asset Management Inc., Virtu Financial LLC and California State Teachers Retirement System. View Insider Buying and Selling for Achillion Pharmaceuticals.

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACHN stock can currently be purchased for approximately $6.24.

Achillion Pharmaceuticals has a market capitalization of $873.91 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.View Additional Information About Achillion Pharmaceuticals.

The official website for Achillion Pharmaceuticals is http://www.achillion.com/.

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.